SELLAS Life Sciences Group (SLS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

SELLAS Life Sciences Group

NasdaqCM•Healthcare•Biotechnology

$11.66+0.37(0.03%)Pre-market

Market Cap

$2.17B

P/B

15.8x

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (6/25).

Profitability8/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality10/25

Strengths

Long cash runwayInterest easily coveredCash-backed earningsNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 49.2x5y range 11.3x – 49.2x

Currently near its 6-quarter median.

P/B · 15.8x5y range 2.4x – 27.1x

Currently above its 18-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.17B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-35.22M
TTM Op. Income: $-35.22M
Q. Op. Income: $-10.63M
TTM Net Income: $-32.46M
Q. Net Income: $-9.61M
EPS: $-0.05
Shares Out.: $189.18M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-35.22M and TTM operating income of $-35.22M show growth is flowing through to the bottom line. However, net income is negative at $32.46M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -1062900000.0%
Net Margin: -960500000.0%

Op. margin of -1062900000.0% is down 375600000.0% YoY — costs are rising relative to revenue. Net margin at -960500000.0% Across the last 8 quarters, operating margin has fallen for 5 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 15.8x

P/S of 0.0x and P/B of 15.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $145.38M
Cash: $138.34M
Long-Term Debt: N/A
Book Value: $137.66M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-7.59M
TTM Free Cash Flow: $-28.42M
FCF Margin: N/A
FCF / Net Income: 0.9

TTM FCF of $-28.42M on $-7.59M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 9% — a weakening trend.